UPPSALA, Sweden, Oct. 25, 2018 /PRNewswire/ — The win in the patent litigation strengthen Orexo’s long term business opportunities Q3 2018 highlights Orexo wins appeal against Actavis on Zubsolv patent in the US, expiring in 2032 Total net revenues of SEK 216.6 million (166.2), up 30.3…

Source: https://www.prnewswire.com:443/news-releases/orexo—interim-report-q3-2018-300737664.html

This entry was posted on Thursday, October 25th, 2018 at 1:10 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.